S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:AZRX

AzurRx BioPharma News Headlines

$1.21
+0.03 (+2.54 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.06
Now: $1.21
$1.24
50-Day Range
$0.87
MA: $1.52
$2.17
52-Week Range
$0.37
Now: $1.21
$2.63
Volume1.88 million shs
Average Volume11.15 million shs
Market Capitalization$91.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Headlines

AzurRx BioPharma (NASDAQ AZRX) News Headlines Today

Source:
SourceHeadline
AzurRx BioPharma (NASDAQ:AZRX) Trading Down 6.5%AzurRx BioPharma (NASDAQ:AZRX) Trading Down 6.5%
americanbankingnews.com - March 3 at 8:06 PM
 Brokerages Anticipate AzurRx BioPharma, Inc. (NASDAQ:AZRX) Will Post Earnings of -$0.13 Per Share Brokerages Anticipate AzurRx BioPharma, Inc. (NASDAQ:AZRX) Will Post Earnings of -$0.13 Per Share
americanbankingnews.com - March 3 at 6:36 PM
AzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences ConferenceAzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 9:23 AM
AzurRx BioPharma (NASDAQ:AZRX) Stock Price Down 10.7%AzurRx BioPharma (NASDAQ:AZRX) Stock Price Down 10.7%
americanbankingnews.com - February 25 at 9:42 PM
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the BoardBioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board
marketwatch.com - February 25 at 12:46 AM
AzurRx BioPharma (NASDAQ:AZRX) Trading 14.2% Higher AzurRx BioPharma (NASDAQ:AZRX) Trading 14.2% Higher
americanbankingnews.com - February 24 at 7:20 PM
AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of DirectorsAzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors
finance.yahoo.com - February 24 at 9:45 AM
AzurRx BioPharma (NASDAQ:AZRX)  Shares Down 5.7% AzurRx BioPharma (NASDAQ:AZRX) Shares Down 5.7%
americanbankingnews.com - February 18 at 7:46 PM
AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland ConferenceAzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference
finance.yahoo.com - February 16 at 7:50 AM
AzurRx BioPharma, Inc. (NASDAQ:AZRX) Short Interest Up 169.8% in JanuaryAzurRx BioPharma, Inc. (NASDAQ:AZRX) Short Interest Up 169.8% in January
americanbankingnews.com - February 12 at 4:22 AM
AzurRx BioPharma (NASDAQ:AZRX)  Shares Down 7.9% AzurRx BioPharma (NASDAQ:AZRX) Shares Down 7.9%
americanbankingnews.com - February 11 at 9:42 PM
Zacks: Brokerages Anticipate AzurRx BioPharma, Inc. (NASDAQ:AZRX) Will Announce Earnings of -$0.13 Per ShareZacks: Brokerages Anticipate AzurRx BioPharma, Inc. (NASDAQ:AZRX) Will Announce Earnings of -$0.13 Per Share
americanbankingnews.com - February 11 at 4:42 PM
AzurRx BioPharma, Inc. (NASDAQ:AZRX) Expected to Post Earnings of -$0.13 Per ShareAzurRx BioPharma, Inc. (NASDAQ:AZRX) Expected to Post Earnings of -$0.13 Per Share
americanbankingnews.com - February 11 at 4:42 PM
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Collaboration for Planned Phase 2 Clinical Trial of FW-1022BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Collaboration for Planned Phase 2 Clinical Trial of FW-1022
marketwatch.com - February 10 at 9:25 AM
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in BIO CEO & Investor Digital ConferenceBioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in BIO CEO & Investor Digital Conference
marketwatch.com - February 9 at 7:29 AM
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal InfectionsAzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
finance.yahoo.com - February 9 at 7:29 AM
AzurRx BioPharma to Present at BIO CEO & Investor Digital ConferenceAzurRx BioPharma to Present at BIO CEO & Investor Digital Conference
finance.yahoo.com - February 8 at 11:27 AM
AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819
finance.yahoo.com - January 28 at 10:15 AM
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis PatientsAzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients
finance.yahoo.com - January 26 at 11:23 AM
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis PatientsAzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
finance.yahoo.com - January 21 at 8:40 AM
AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal InfectionsAzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
finance.yahoo.com - January 12 at 8:59 AM
AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 ConferenceAzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference
finance.yahoo.com - January 7 at 12:12 PM
AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual ConferenceAzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
finance.yahoo.com - January 6 at 10:50 AM
AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access EventAzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event
finance.yahoo.com - January 5 at 1:00 PM
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal InfectionsAzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
finance.yahoo.com - January 4 at 9:52 AM
AzurRx BioPharma Announces $8.0 Million OfferingsAzurRx BioPharma Announces $8.0 Million Offerings
finance.yahoo.com - January 4 at 9:52 AM
AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patientsAzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients
seekingalpha.com - November 30 at 4:59 PM
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic InsufficiencyAzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
finance.yahoo.com - November 30 at 8:40 AM
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James SapirsteinInvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein
finance.yahoo.com - November 24 at 8:51 AM
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis PatientsAzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients
finance.yahoo.com - November 17 at 10:08 AM
AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug ProductionAzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production
finance.yahoo.com - November 10 at 12:46 PM
AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic AlternativesAzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives
finance.yahoo.com - October 29 at 12:48 PM
AzurRx BioPharma Announces Formation of Scientific Advisory BoardAzurRx BioPharma Announces Formation of Scientific Advisory Board
finance.yahoo.com - October 21 at 9:10 AM
AzurRx Bio activates additional trial sites for lead candidateAzurRx Bio activates additional trial sites for lead candidate
seekingalpha.com - October 14 at 1:04 PM
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual ConferenceAzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
finance.yahoo.com - September 15 at 11:27 AM
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
finance.yahoo.com - August 31 at 12:15 PM
AZRX: 1H:21 Readout for OPTION 2 and Combo TrialsAZRX: 1H:21 Readout for OPTION 2 and Combo Trials
finance.yahoo.com - August 26 at 1:30 PM
AzurRx BioPharma, Inc.: AzurRx BioPharma to Present at The LD 500 Virtual ConferenceAzurRx BioPharma, Inc.: AzurRx BioPharma to Present at The LD 500 Virtual Conference
finanznachrichten.de - August 18 at 12:23 PM
AzurRx BioPharma launches European arm of cystic fibrosis studyAzurRx BioPharma launches European arm of cystic fibrosis study
seekingalpha.com - August 17 at 12:50 PM
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic FibrosisAzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
finance.yahoo.com - August 17 at 12:50 PM
Dosing underway in AzurRx Bios OPTION 2 trial of MS1819 in cystic fibrosisDosing underway in AzurRx Bio's OPTION 2 trial of MS1819 in cystic fibrosis
seekingalpha.com - August 13 at 1:38 PM
AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic FibrosisAzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
finance.yahoo.com - August 13 at 8:37 AM
AZRX: MS1819 Update: Interim DataAZRX: MS1819 Update: Interim Data
finance.yahoo.com - August 12 at 5:35 PM
AzurRx BioPharma CEO Issues Clarifying Statement to ShareholdersAzurRx BioPharma CEO Issues Clarifying Statement to Shareholders
finance.yahoo.com - August 12 at 5:35 PM
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go PrivateThe Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
finance.yahoo.com - August 12 at 12:35 PM
AzurRx rallies 41% on positive data on lead candidateAzurRx rallies 41% on positive data on lead candidate
seekingalpha.com - August 11 at 9:21 PM
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic InsufficiencyAzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
finance.yahoo.com - August 11 at 4:20 PM
AZRX: Capital Raise, OPTION 2 Trial UnderwayAZRX: Capital Raise, OPTION 2 Trial Underway
finance.yahoo.com - July 27 at 1:04 PM
AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites ActivatedAzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated
finance.yahoo.com - July 22 at 8:45 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AzurRx BioPharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AzurRx BioPharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - July 22 at 8:45 AM
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.